UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.

October 10, 2025

Vol.51 No.37

Clinical Roundup

New therapy delays progression of recurrent prostate cancer, UCLA study shows

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy went more than twice as long without their disease worsening compared with those who received SBRT alone, according to new clinical trial results from UCLA Health Jonsson Comprehensive Cancer Center researchers.

October 03, 2025

Vol.51 No.36

In Brief

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Mammograms may benefit women well into their 80s, UCLA study finds

For many older women, the question of whether to continue breast cancer screening has been uncertain. While most guidelines recommend mammograms up to age 74, advice for women 75 and older has been less clear.

September 26, 2025

Vol.51 No.35

Drugs & Targets

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Sept. 19 for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab.

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

YOU MAY BE INTERESTED IN

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

New therapy delays progression of recurrent prostate cancer, UCLA study shows

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

Mammograms may benefit women well into their 80s, UCLA study finds

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Renew today!

Subscriber content

Never miss an issue!

Login